Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer

Author： Sherrill Beth   Di Leo Angelo   Amonkar Mayur M.   Wu Yun   Zvirbule Zanete   Aziz Zeba   Bines Jose   Gomez Henry L.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.26, Iss.4, 2010-04, pp. : 767-775

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2++ metastatic breast cancer with letrozole alone or in combination with lapatinib

By Sherrill Beth   Sherif Bintu   Amonkar Mayur M.   Maltzman Julie   O’Rourke Lisa   Johnston Stephen  

Current Medical Research and Opinion, Vol. 27, Iss. 12, 2011-12 ,pp. : 2245-2252

Informa Healthcare

Access to resources Recommend Favorite

Quality‐adjusted time without symptoms or toxicity (Q‐TWiST): patient‐reported outcome or mathematical model? A systematic review in cancer

By  

PSYCHO-ONCOLOGY (ELECTRONIC), Vol. 24, Iss. 3, 2015-03 ,pp. : 253-261

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 129-135

Karger

Access to resources Recommend Favorite

Paclitaxel, Epirubicin and Cyclophosphamide Combination in First-Line Treatment of Metastatic Breast Cancer: A Dose Escalation Study

By  

Oncology, Vol. 66, Iss. 3, 2004-06 ,pp. : 185-191

Karger

Access to resources Recommend Favorite

Quality-adjusted survival as an end point in breast cancer trials

By Martin AJ   Simes RJ  

Clinical Investigation, Vol. 3, Iss. 6, 2013-06 ,pp. : 545-555

Future Science

Access to resources Recommend Favorite